At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Acute/Chronic Infectious Disease
  • Location: Europe


The OPTObacteria consortium aims to develop a multi-analyte and automatic laboratory detector (ALD) for antibiotic-resistant infections. The goal is to detect these analytes within four to six hours from the sample collection, provide a report with the actual patient status, and predict emerging drug resistance through the companion epidemiology software. The platform technology is an opto-electronic device, in which the appropriate ligand-probe, linked onto an opto-electronic surface, will be able to specifically recognize biomolecules of the resistant infections.


The OPTObacteria consortium is a European-funded effort to advance a new technology (engineering approach based on optimized optical fiber system) for the identification of a drug-resistance profile. Highly specific ligands for enzymes class referred to as ESBLs (medicinal-ligand chemistry/microbiology approach) and others such as Methicillin-resistant Staphylococcus aureus (MRSA), will be detected as a first application of the new methods.

The consortium aims to validate the technology in vitro (during the two-year project) as a diagnostic tool. This tool will be able to perform detection against ESBLs, and other proteins involved in the resistance process, directly in the biofluid, without, or in limited broth incubation for bacterial growing. A second method will provide an antibiotic sensitivity test through monitoring bacterial growth in drug resistant infections and to provide an antibiogram-like report. Prescribed antibiotics will be given in a miniaturized cell culture device and tested over a short time period (four to eight hours), and the antibiogram-like report will be evaluated, shortening the time to diagnosis.

The aims of the consortium are to advance the following:


OPTObacteria is funded through the European Union Seventh Framework Programme via Project No. 286998.



Points of Contact

Alberto Venturelli
Tydock Pharma s.r.l.
Via Campi, 183 – 41125
Modena - Italy
phone: +390592055143
email: a.venturelli@tydockpharma.com

Sponsors & Partners

Agencia Estatal Consejo Superior De Investigaciones Cientificas

Centro Regionale Information Communication Technology scrl

Consiglio Nazionale Delle Ricerche

Molecular Discovery Ltd.

Optosmart s.r.l.

Proyeccion Europlan Xxi S.L.

Tydock Pharma s.r.l.

Universita Degli Studi Di Modena E Reggio Emilia

Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.